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Abstract: Drug treatment of Juvenile myoclonic epilepsy (JME) is mainly based on clinical 
experience and prospective and retrospective studies, with little evidence from randomized 
clinical trials. There are no head-to-head comparisons between old and new antiepileptic drugs 
(AEDs) and no drugs licensed speciﬁ  cally for JME. Valproate is unquestionably the drug of the 
ﬁ  rst choice in men with JME. In women, lamotrigine should be preferred regarding teratogenic-
ity and side effects of valproate. In addition, levetiracetam and topiramate are effective and can 
be use in combination or as second line treatment. Some AEDs can aggravate JME. In addition 
of AEDs, non-pharmacological treatments are important in JME. JME usually require lifelong 
treatment because seizures nearly always return after withdrawal of therapy.
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Introduction
Juvenile myoclonic epilepsy (JME) is a common epilepsy syndrome that is classiﬁ  ed 
among the idiopathic generalized epilepsies (IGEs) (ILAE 1989). It is a collection 
of seizure patterns that are clinically distinct from those in other forms of IGE, with 
the major characteristic being adolescence-onset myoclonic seizures. Although the 
pathogenesis is unknown, recent advances, especially in genetics, suggest several 
possible mechanisms. JME is both genetically and clinically heterogeneous; some 
clinical differences may indicate differences in pathogenesis in different groups of 
patients. The nosology and classiﬁ  cation of IGE syndromes are currently under revision 
(Andermann and Berkovic 2001; Engel 2001). JME is characterized by a particular 
pharmacological sensitivity. Valproate has a speciﬁ  c potency. Others antiepileptic 
drugs (AEDs) are also efﬁ  cient, such as lamotrigine, clonazepam, topiramate and 
levetiracetam, while others may have aggravating effects.
Electroclinical features of juvenile myoclonic epilepsy
JME is a common IGE that is characterized by myoclonic seizures. It is the most 
common IGE in adults, especially in women. Isolated myoclonic jerks of the arms, 
especially shortly after awakening, are characteristic. Generalized tonic-clonic seizures 
often occur, and one-third of individuals have absences. The generalized tonic-clonic 
seizures are often preceded by a few minutes of generalized myoclonus of increasing 
frequency and intensity. They occur predominantly after awakening. Seizure occur-
rence is more likely with sleep deprivation, fatigue and alcohol withdrawal. Onset is 
usually in adolescence but seizures may begin or be diagnosed only in the early 20s. 
Eighty percent of patients with JME begin having seizures between ages 12 and 18. 
The mean age of onset for generalized tonic clonic seizures is 15.5-years. The most 
important element in the diagnosis of JME is the clinical history.
The typical abnormality on electroencephalography (EEG) is bilateral mul-
tiple spike or polyspike-wave complexes which precede a myoclonic jerk. The Neuropsychiatric Disease and Treatment 2007:3(6) 730
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EEG discharge includes 5–20 spikes with a frequency 
between 12 and 16 Hz. The amplitude of spikes is frequently 
maximal in anterior areas. An ictal recording is best obtained 
by polygraphic video-EEG performed a provoked early 
morning awakening during a full-night sleep recording or 
at least after noctural sleep deprivation.
JME is one of the epileptic syndrome clearly associated with 
photosensitivity occurring in about 30% (Janz 1985; Loiseau and 
Duche 1990). Myoclonic seizure can be induced by intermittent 
luminous stimulation in photosensitive patients, but clinical pho-
tosensitivity is less frequent than during EEG recording.
In some cases, focal clinical or EEG features or both in 
patients with JME can be observed. These features include 
not only unilateral myoclonic jerks but also version and 
asymmetrical tonic limb posturing (Aliberti et al 1994; 
Lancman et al 1994; Usui et al 2005).
Misdiagnosis and delayed diagnosis remain common, as 
reported in the literature (Grunewald et al 1992; Atakli et al 
1998). Patients frequently come to medical attention only 
after a generalized convulsion, and the history of much earlier 
myoclonic jerks is then often obtained only retrospectively 
(Grunewald et al 1992).
Treatment
The goal of management is to render the individual seizure-
free without the side effect of the medication. JME require 
lifelong treatment because seizures nearly always return after 
withdrawal of therapy (Delgado-Escueta and Enrile-Bascal 
1984; Baruzzi et al 1998). JME is difﬁ  cult to treat in about 15% 
of patients. The predictors of pharmacoresistance include: 
(1) the coexistence of all three seizures types (myoclonic 
jerks, absence seizures and GTCS), (2) the existence of asso-
ciated psychiatric problems, and (3) focal clinical symptoms 
and/or focal EEG discharge (Dasheiff and Ritaccio 1993; 
Fernando-Dongas et al 2000; Gelisse et al 2001).
Non-pharmacological treatment
In JME, lack of sleep and alcohol intake can induce sei-
zures. The sleep-wake rhythm has to be regulated. The 
circumstances interfering with normal sleep and progressive 
awakening in the morning should be eliminated. If the patient 
stays up late at night, he should sleep longer the next morn-
ing. Alcoholic drinks will only permitted in small quantities, 
on social occasions. Patients should be advised not to drink 
in cases of lack of sleep. If the patient has photosensitivity, 
they should avoid relevant visual stimuli. Some maneuvers 
reduce the risk of photosensitive seizures, including monocul 
complete occlusion, increased distance from a video-display 
terminal, and the provision of ambient back lighting (Harding 
and Jeavons 1992). We suggest these approaches to patients 
who show photosensitivity on EEG but do not know how 
successful these environmental alterations are in JME.
Valproate
Mechanism of action
Valproic acid is a branched-chain fatty acid that markedly differs 
in structure from all other AEDS in clinical use. Its mechanism 
of action remains not fully understand. There are evidences that 
valproic acid increases GABA concentrations, the mechanism 
by which this occurs remains unknown. A number of mecha-
nisms have been proposed, including inhibition of GABA-T 
action, activation of GABA synthesis by an increase of GAD 
activity, and increased release of GABA into the synapse.
Efﬁ  cacy
Based on clinical experience, valproate was ﬁ  rst proposed as 
a treatment of myoclonic seizure. 22-years ago, the sensitivity 
of VPA was reported (Delgado-Escueta and Enrile-Bascal 
1984). Although JME is an important syndrome, there have 
been almost no randomized clinical trials conducted using any 
medication for its treatment. However, there have been many 
open case studies conducted with VPA in JME management. 
The open series that have been published using VPA show 
a 41%–88% seizure-free rate for patients receiving VPA, 
either as an add-on medication or as monotherapy (Atakli 
et al 1998; Kleveland and Engelsen 1998). Case studies have 
also shown that a low, once-daily dose (500 mg) of VPA can 
effectively control JME and keep patients seizure free for as 
long as 2-years (Panagariya et al 2001; Karlovassitou-Koriari 
et al 2002). Newer studies that examined the efﬁ  cacy of 
lamotrigine, topiramate and valproate in JME have all shown 
that valproate has the best efﬁ  cacy of the three (Prasad et al 
2003; Nicolson et al 2004; Mohanraj and Brodie 2005).
Valproate is today one of the most effective AEDs in 
JME. He should be considered the ﬁ  rst line drug at least for 
man. Taking into an account the teratogenicity (possibly 
lessened by the concurrent use of folic acid) and some side 
effects (weight gain), VPA are often considered unacceptable 
in young women of childbearing age.
Benzodiazepin
Mechanism of action
The benzodiazepines work by primarily enhancing gamma-
aminobutyric acid (GABA)ergic inhibition by binding to the 
benzodiazepine receptor on GABAA receptors (Rudolph 
et al 1999).Neuropsychiatric Disease and Treatment 2007:3(6) 731
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Efﬁ  cacy
Clonazepam can also be effective in the treatment of JME. 
Obeid and Panayiotopoulos (1989) treated 17 patients who 
had JME with Clonazepam. All of the patients had myoclonic 
seizures before treatment, and 14 of the 17 had GTC seizures 
before treatment. After Clonazepam treatment, myoclonic 
seizures were controlled in 15 (88%) of 17 patients, and 
the remaining two patients had a 75% reduction in seizure 
frequency. However, Clonazepam did not produce effec-
tive results for reducing GTC seizures. Six (43%) of the 
14 patients with GTC seizures were controlled. In addition, 
two patients sustained injuries during GTC seizures because 
Clonazepam eliminated their myoclonic seizures, which 
had served as a warning, and they went directly into a GTC 
seizure. The authors concluded that Clonazepam, while effec-
tive in treating myoclonic seizures, probably should not be 
used to control GTC seizures.
Lamotrigine
Mechanism of action
Lamotrigine is a phenyltriazine derivative. Lamotrigine acts 
through inhibition of voltage-activated sodium channels and 
possibly calcium channels, so that it prevents the release of 
glutamate (Lees and Leach 1993).
Efﬁ  cacy
Lamotrigine is effective in controlling generalized tonic 
clonic seizure and absence while there are some reports 
of myoclonic seizures exacerbation (Biraben et al 2000; 
Carrazana and Wheeler 2001).
Many studies performed over recent years have 
demonstrated clinical utility for the treatment of JME. An 
Open-label study to evaluate lamotrigine as an alternative to 
valproate (63 patients switched from valproate to lamotrigine) 
demonstrated an improvement in 67% of patients. No aggra-
vation of clinical symptoms was also reported (Morris et al 
2004). Buchanan conducted a study of 12 patients with JME 
who were treated with LTG monotherapy (Buchanan 1996). 
Five (41%) of these 12 patients became seizure free while 
receiving LTG monotherapy, and the authors concluded 
that LTG might be effective in the management of JME. 
In a retrospective study, valproate monotherapy (n = 36) 
and lamotrigine monotherapy (n = 14) were compared, as 
well valproate (n = 22), lamotrigine (n = 21) and topiramate 
polytherapy (n = 15) were compared. The results suggested 
that lamotrigine were an effective option as monotherapy 
and polytherapy (Prasad et al 2003). Furthermore, the 
efﬁ  cacy of lamotrigine in JME was evaluated in bitherapy. 
The polytherapy is especially interesting in case of drug 
resistance. The combination of lamotrigine with valproate 
appears to be synergistic in many type of epilepsy. But the 
same combination is lead to an increased risk to develop an 
important skin rash (Gerike et al 1999; Pisani et al 1999).
Levetiracetam
Mechanism of action
Levetiracetam is a pyrrolidone derivative, is the S-enantiomer 
of the ethyl analogue of piracetam. While the exact mecha-
nism of action of levetiracetam is not known, it appears to 
act via a speciﬁ  c binding site within the brain (but does not 
directly affect GABA or glutamate), does not alter sodium 
channel properties, produces a limited reduction in high-
voltage-activated calcium currents, and possibly modulates 
intracellular calcium transients (Herdon et al 1997; Zona et al 
2001). Molecular studies involving transgenic mice suggest 
that levetiracetam binds to a synaptic vesicle protein (SVA2) 
that is involved in vesicle neurotransmitter exocytosis, and 
that the binding afﬁ  nity to SVA2 is directly proportional to 
seizure protection (Lynch et al 2004).
Efﬁ  cacy
Levetiracetam is probably the best new AED in the treat-
ment of JME and may replace valproate for the treatment 
of the disorder because of high and sustained efﬁ  cacy, fast 
action, and an excellent safety proﬁ  le. More than 60% of 
patients with intractable JME became seizure-free with 
levetiracetam monotherapy or polytherapy (Czapinski and 
Czapinska 2004; Resor and Resor 2005). Resor and col-
leagues assessed levetiracetam monotherapy in 24 patients 
with JME and GTCS (Resor and Resor 2005). Sixteen 
patients (66.7%) became free of GTCS; three of them had 
a single convulsive seizure after either stopping leveti-
racetam for 24 h or reducing the dose to 500 mg/day but 
subsequently have remained free of convulsive seizures. 
Myoclonic seizures were effectively controlled in 22 of 
24 patients. Moreover, Sharpe and colleagues performed a 
retrospective review on the medical record of 30 patients 
with JME, whose age was between 5 and 21-years, treated 
with levetiracetam with dosage range from 12 to 50 mg/kg/j 
(Sharpe et al 2005). The length of follow-up was 27-months. 
24 patients (80%) became seizure free with levetiracetam 
monotherapy and 2 additional patients had an improvement 
of seizure control. Andermann and colleagues evaluated 
levetiracetam in 122 patients (113 with JME and 9 with 
juvenile absence epilepsy). The study was a double-bind 
multicenter placebo controlled trial conducted in patients Neuropsychiatric Disease and Treatment 2007:3(6) 732
Auvin
without control on one AED. The responder rate was 58.3% 
with levetiracetam versus 23.3% with placebo (Andermann 
et al 2005). Specchio et al conducted a multicenter, pro-
spective open-label study in patients with JME (Specchio 
et al 2006). 10 patients were newly diagnosed and 38 were 
resistant and/or intolerant to previous AED. 5 patients 
dropped out. 18 patients (37.5%) were without myoclonia 
and 35 (73%) had no generalized tonic seizure.
Topiramate
Mechanism of action
Topiramate is a sulphamate-substituted monosaccharide that 
exhibits some inhibition of carbonic anhydrase. Its AED 
activity is independent of this effect. Topiramate has multiple 
modes of action, including modulation of voltage-dependent 
sodium channels, potentiation of GABAergic inhibition at 
a novel site on the GABAA receptor, and possible action at 
non-Nmethyl- D-aspartate (NMDA) receptors (Hanaya et al 
1998; White et al 2000; Zona et al 1997).
Efﬁ  cacy
Several studies have shown the usefulness of topiramate 
in patients with JME. There is one randomized-controlled 
study on the efﬁ  cacy of topiramate in patients with general-
ized tonic clonic seizure including patients with JME (Biton 
et al 2005). A reduction of more than 50% of generalized 
tonic clonic seizure were reported in 8/11 patients treated 
by topiramate compare to 2/11 in placebo-treated patients. 
A reduction in myoclonic and absence seizures was also 
reported but did not achieve statistical signiﬁ  cance. Topira-
mate efﬁ  cacy and tolerability were evaluated in 22 patients 
with JME (Sousa Pda et al 2005). 16 patients completed the 
ﬁ  rst year of the follow-up, while 4 left the study because of 
poor seizure control and 2 because of low compliance. Myo-
clonic seizures were controlled in 11 patients and persisted in 
5 patients. Generalized tonic clonic seizures were completely 
controlled in 10 patients, 4 patients had more than 50% 
reduction of seizures and 2 had reduction less than 50%. In 
a randomized open-label treatment, 28 patients with a recent 
diagnosed JME received topiramate or valproate (Levisohn 
et al 2003). 12 of 19 patients treated by topiramte completed 
the study, while 7 of 9 patients treated by valproate com-
pleted the study. Generalized tonic clonic, myoclonic and 
absence seizures were totally controlled in 10/12, 9/14 and 
2/2 topiramate-treated patients, respectively, and 3/4, 7/9 
and 1/2 valproate-treated patients. In a retrospective cohort, 
topiramate monotherapy and polytherapy were considered 
as an alternative to VPA (Prasad et al 2003).
Zonisamide
Mechanism of action
Zonisamide by blocking the voltage-sensitive sodium 
channels prevents repetitive neuronal ﬁ  ring. It also reduces 
voltage-dependent T-type calcium channels, facilitates 
dopaminergic and serotoninerigic neurotransmission, weakly 
inhibits carbonic anhydrase and may protect neurones from 
free-radical damage, thereby stabilizing neuronal membranes 
(Suzuki et al 1992; Kito et al 1996).
Efﬁ  cacy
Few studies focused on the effects of zonisamide are 
available. A retrospective study analyzing 15 patients (mono-
therapy in 13 patients and added to valproate in 2 patients) 
reported a good control of seizures. 69%, 62%, and 38% 
were free for generalized tonic clonic, myoclonic and absence 
seizures, respectively. Side effects were reported in 20% of 
patients (Kothare et al 2004). In a neurophysiological study 
of a patient, zonisamide permits almost complete disappear-
ance of generalized spike and wave discharges (Szaﬂ  arski 
2004). These data suggest the possible useful of this AED 
in JME.
AED aggravating JME
It is now well known that AEDs can aggravate epilepsy. 
Phenytoin and carbamazepine have shown to aggravate 
the myoclonic and absence seizures of JME and therefore 
should be avoided (Genton et al 2000; Gelisse et al 2004; 
Thomas et al 2006). Genton et al (2000) conducted a 
study with CBZ and PHT to determine the risk of seizure 
aggravation in 40 patients with JME. In the CBZ group, 
19 (68%) of 28 patients had a seizure aggravation, usu-
ally affecting the myoclonic seizure, and only six (21%) 
of 28 patients improved. In the PHT group, six (38%) of 
16 patients had a seizure aggravation, and only two (12%) 
of 16 patients improved. Aggravation mostly was in the 
form of increased myoclonic jerks. The authors concluded 
that among commonly prescribed AEDs, CBZ appears 
to have the strongest aggravating potential in patients 
with JME, whereas the aggravating effect of PHT is less 
prominent.
There have been isolated series of reports indicating 
that lamotrigine can exacerbate or aggravate myoclonic 
seizures. Biraben et al reported four patients with JME 
receiving LTG therapy that experienced myoclonus seizure 
aggravation (Biraben et al 2000). Carrazana et al also found 
two patients with JME (2/24) developed dramatic exacerba-
tion of myoclonus and two other (2/24) had mild transient Neuropsychiatric Disease and Treatment 2007:3(6) 733
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increases in morning myoclonus with lamotrigine (Carrazana 
and Wheeler 2001).
Antiepileptic drug selection
When presented with a patient with epilepsy, physicians 
should prescribe the medication that will effectively control 
the seizures yet not endanger the patient with adverse 
events or seizure aggravation. Although JME is an impor-
tant syndrome, there have been no randomized clinical 
trials conducted using any medication for its treatment. 
Drug treatment of JME is mainly based on clinical experi-
ence and prospective and retrospective studies. There are 
no head-to-head comparisons between old and new AEDs 
and no drugs licensed speciﬁ  cally for JME.
The 2001 and 2005 expert consensus surveys on adult 
epilepsies (Karceski et al 2001, 2005) ranked valproate as the 
treatment of choice for idiopathic generalized epilepsy when 
the patient’s sex was not speciﬁ  ed. However, in the 2005 
survey adult epilepsy, when it was speciﬁ  ed that the patient 
was a woman, the experts rated lamotrigine as treatment of 
choice. In the 2005 expert opinion about pediatric epilepsy 
treatment, valproate and lamotrigine was the for 15-year-old 
male with JME, while lamotrigine was the only choice for 
15-year-old female with JME (Wheless et al 2005).
Valproate is unquestionably the drug of the ﬁ  rst choice 
in men with JME. In women, where considerations of tera-
togenicity, weight gain, and polycystic ovary syndrome are 
relevant, other options include levetiracetam, lamotrigine, 
topiramate and perhaps zonisamide. In patients with symp-
toms refractory to treatment with one drug, valproate with 
small doses of lamotrigine is often an effective combination. 
When valproate is undesirable, combining levetiracetam with 
lamotrigine may be effective.
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